Topic

Strategy

10
Jan
2020

Entering JPM20 With a Grounded, Yet Hopeful, View of Health Tech

Health tech seems balanced precariously between excessive optimism and excessive skepticism, between the promise that emerging technology is poised to disrupt health like it has so many other areas, and the painful recognition that many idealistic technologists misunderstood both the scientific and human dimensions of the inordinately complex problems to be solved in both health care services and the development...
Read More
9
Jan
2020

Sanofi’s New CEO Captures Pharma’s Grounded View of Health Tech

Since taking over as Sanofi’s CEO in September, Paul Hudson has been blunt in his assessment of health technology decisions, and indecisions, made by previous management. Early in his tenure, Hudson took square aim at his company’s once-heralded $500 million collaboration with Verily on Onduo. This partnership was started in 2016 and intended to help diabetics better manage their condition. ...
Read More
3
Jan
2018

Scholar Rock, After a Year on Pause, Snags $47M to Take New Tack Against SMA

Spinal muscular atrophy is one of the ongoing success stories in biotech. But that doesn’t mean the story’s over. Cambridge, Mass.-based Biogen won a first-of-its-kind FDA approval a year ago with a new antisense oligonucleotide, licensed from Ionis Pharmaceuticals. The drug, nusinersen (Spinraza), allows kids with a crippling disease to produce greater amounts of the SMN protein they need to...
Read More